SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Sundström Poromaa Inger) ;mspu:(article)"

Sökning: WFRF:(Sundström Poromaa Inger) > Tidskriftsartikel

  • Resultat 1-10 av 305
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Björn, Inger, 1953-, et al. (författare)
  • Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy
  • 2003
  • Ingår i: Journal of Clinical Endocrinology and Metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 88:5, s. 2026-2030
  • Tidskriftsartikel (refereegranskat)abstract
    • Previous studies have indicated that the addition of progestinsduring sequential hormonal replacement therapy (HRT)causes negative mood and physical symptoms. History of premenstrualsyndrome, type of progestin, and dose of progestinhave thus far been shown to influence the progestin-inducedadverse mood symptoms during HRT.The aim of this study was to compare adverse mood effectsof two different doses of estradiol, in combination with a progestin,during postmenopausal HRT. Twenty-eight perimenopausalwomen were included in this randomized, doubleblind,crossover study comparing 2- or 3-mg continuousestradiol, with an addition of 10 mg medroxyprogesteroneacetate on d 17–28 during each treatment cycle. The mainoutcome measures were mood and physical symptoms kept ona daily rating scale. Together with the progestin, the higherdose of estrogen caused significantly more negative moodsymptoms than the lower dose. Tension, irritability, and depressedmood were all significantly augmented during theprogestin phase of cycles with 3mg estradiol (P<0.001). Physicalsymptoms also increased during the progestin phase of3-mg estradiol cycles (P<0.001), whereas positive mood symptomswere less affected. The only positive mood that changedwith estrogen dose was friendliness, which decreased duringthe progestin phase of high estradiol cycles compared withcycles with lower estradiol (P < 0.05).Our conclusion is that an increase of the estrogen doseaccentuates negativemoodand physical symptoms during theprogestin phase of sequential hormonal therapy.
  •  
2.
  • Björn, Inger, 1953-, et al. (författare)
  • The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy
  • 2002
  • Ingår i: Gynecological Endocrinology. - : Informa Healthcare. - 0951-3590 .- 1473-0766. ; 16, s. 1-8
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to compare adverse mood effects of two different doses of medroxyprogesterone acetate (MPA) during postmenopausal hormone replacement therapy (HRT) in women with and without a history of premenstrual syndrome (PMS). The study was designed as a randomized double-blind cross-over study and included 36 postmenopausal women at three health care areas in northern Sweden. The women received 2 mg estradiol continuously during five 28-day cycles and 10 mg or 20 mg MPA sequentially for 12 days during each cycle. The main outcome measures were mood and physical symptoms noted on a daily rating scale. We found that physical symptoms did not differ between 10 and 20 mg MPA. Both women with a history of PMS and women without responded with more negative mood symptoms with the lower dose of MPA. In women with previous PMS the higher dose of MPA enhanced positive mood symptoms. With respect to mood and physical symptoms, the aim to lower MPA doses in HRT is unwarranted.
  •  
3.
  • Bäckström, Torbjörn, et al. (författare)
  • The role of hormones and hormonal treatments in premenstrual syndrome
  • 2003
  • Ingår i: CNS Drugs. - 1172-7047 .- 1179-1934. ; 17:5, s. 325-342
  • Tidskriftsartikel (refereegranskat)abstract
    • Premenstrual syndrome (PMS) is a menstrual cycle-linked condition with both mental and physical symptoms. Most women of fertile age experience cyclical changes but consider them normal and not requiring treatment. Up to 30% of women feel a need for treatment. The aetiology is still unclear, but sex steroids produced by the corpus luteum of the ovary are thought to be symptom provoking, as the cyclicity disappears in anovulatory cycles when a corpus luteum is not formed. Progestogens and progesterone together with estrogen are able to induce similar symptoms as seen in PMS. Symptom severity is sensitive to the dosage of estrogen. The response systems within the brain known to be involved in PMS symptoms are the serotonin and GABA systems. Progesterone metabolites, especially allopregnanolone, are neuroactive, acting via the GABA system in the brain. Allopregnanolone has similar effects as benzodiazepines, barbiturates and alcohol; all these substances are known to induce adverse mood effects at low dosages in humans and animals. SSRIs and substances inhibiting ovulation, such as gonadotrophin-releasing hormone (GnRH) agonists, have proven to be effective treatments. To avoid adverse effects when high dosages of GnRH agonists are used, add-back hormone replacement therapy is recommended. Spironolactone also has a beneficial effect, although not as much as SSRIs and GnRH agonists.
  •  
4.
  • Lindholm, Åsa, et al. (författare)
  • Effect of sibutramine on weight reduction in women with polycystic ovary syndrome : a randomized, double-blind, placebo-controlled trial
  • 2008
  • Ingår i: Fertility and Sterility. - : Elsevier BV. - 0015-0282 .- 1556-5653. ; 89:5, s. 1221-1228
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS). DESIGN: Investigator-initiated, multicenter, double-blind, randomized, parallel-group clinical trial. SETTING: Departments of Obstetrics and Gynecology in primary care, referral centers, and private practice. PATIENT(S): Forty-two patients with confirmed PCOS were included in the study, and 34 patients completed the study. INTERVENTION: Sibutramine 15 mg once daily together with brief lifestyle modification was compare with placebo together with brief lifestyle modification. MAIN OUTCOME MEASURE(S): The primary endpoint was to assess weight loss. Secondary endpoints included the efficacy of sibutramine for treatment of menstrual pattern and cardiovascular risk factors. RESULT(S): After 6 months the sibutramine group had lost 7.8 +/- 5.1 kg compared with a weight loss of 2.8 +/- 6.2 kg in the placebo group. Sibutramine treatment resulted in significant decreases in apolipoprotein B, apolipoprotein B/apolipoprotein A ratio, triglycerides, and cystatin C levels. CONCLUSION(S): Sibutramine in combination with lifestyle intervention results in significant weight reduction in obese patients with PCOS. In addition to the weight loss, sibutramine seems to have beneficial effects on metabolic and cardiovascular risk factors.
  •  
5.
  •  
6.
  • Wallin Lundell, Inger, et al. (författare)
  • How women perceive abortion care : A study focusing on healthy women and those with mental and posttraumatic stress
  • 2015
  • Ingår i: European journal of contraception & reproductive health care. - : Informa UK Limited. - 1362-5187 .- 1473-0782. ; 20:3, s. 211-222
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives To identify perceived deficiencies in the quality of abortion care among healthy women and those with mental stress. Methods This multi-centre cohort study included six obstetrics and gynaecology departments in Sweden. Posttraumatic stress (PTSD/PTSS) was assessed using the Screen Questionnaire-Posttraumatic Stress Disorder; anxiety and depressive symptoms, using the Hospital Anxiety Depression Scale; and abortion quality perceptions, using a modified version of the Quality from the Patient's Perspective questionnaire. Pain during medical abortion was assessed in a subsample using a visual analogue scale. Results Overall, 16% of the participants assessed the abortion care as being deficient, and 22% experienced intense pain during medical abortion. Women with PTSD/PTSS more often perceived the abortion care as deficient overall and differed from healthy women in reports of deficiencies in support, respectful treatment, opportunities for privacy and rest, and availability of support from a significant person during the procedure. There was a marginally significant difference between PTSD/PTSS and the comparison group for insufficient pain alleviation. Conclusions Women with PTSD/PTSS perceived abortion care to be deficient more often than did healthy women. These women do require extra support, relatively simple efforts to provide adequate pain alleviation, support and privacy during abortion may improve abortion care.
  •  
7.
  •  
8.
  • Wallin Lundell, Inger, et al. (författare)
  • Neuroticism-related personality traits are associated with posttraumatic stress after abortion : findings from a Swedish multi-center cohort study
  • 2017
  • Ingår i: BMC Women's Health. - : Springer Science and Business Media LLC. - 1472-6874. ; 17:1
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Most women who choose to terminate a pregnancy cope well following an abortion, although some women experience severe psychological distress. The general interpretation in the field is that the most consistent predictor of mental disorders after induced abortion is the mental health issues that women present with prior to the abortion. We have previously demonstrated that few women develop posttraumatic stress disorder (PTSD) or posttraumatic stress symptoms (PTSS) after induced abortion. Neuroticism is one predictor of importance for PTSD, and may thus be relevant as a risk factor for the development of PTSD or PTSS after abortion. We therefore compared Neuroticism-related personality trait scores of women who developed PTSD or PTSS after abortion to those of women with no evidence of PTSD or PTSS before or after the abortion.METHODS: A Swedish multi-center cohort study including six Obstetrics and Gynecology Departments, where 1294 abortion-seeking women were included. The Screen Questionnaire-Posttraumatic Stress Disorder (SQ-PTSD) was used to evaluate PTSD and PTSS. Measurements were made at the first visit and at three and six month after the abortion. The Swedish universities Scales of Personality (SSP) was used for assessment of Neuroticism-related personality traits. Multiple logistic regression analyses were performed to investigate the risk factors for development of PTSD or PTSS post abortion.RESULTS: Women who developed PTSD or PTSS after the abortion had higher scores than the comparison group on several of the personality traits associated with Neuroticism, specifically Somatic Trait Anxiety, Psychic Trait Anxiety, Stress Susceptibility and Embitterment. Women who reported high, or very high, scores on Neuroticism had adjusted odds ratios for PTSD/PTSS development of 2.6 (CI 95% 1.2-5.6) and 2.9 (CI 95% 1.3-6.6), respectively.CONCLUSION: High scores on Neuroticism-related personality traits influence the risk of PTSD or PTSS post abortion. This finding supports the argument that the most consistent predictor of mental disorders after abortion is pre-existing mental health status.
  •  
9.
  •  
10.
  • Wallin Lundell, Inger, et al. (författare)
  • Posttraumatic stress among women after induced abortion : a Swedish multi-centre cohort study
  • 2013
  • Ingår i: BMC Women's Health. - : BioMed Central. - 1472-6874. ; 13, s. Article Number: 52-
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Induced abortion is a common medical intervention. Whether psychological sequelae might follow induced abortion has long been a subject of concern among researchers and little is known about the relationship between posttraumatic stress disorder (PTSD) and induced abortion. Thus, the aim of the study was to assess the prevalence of PTSD and posttraumatic stress symptoms (PTSS) before and at three and six months after induced abortion, and to describe the characteristics of the women who developed PTSD or PTSS after the abortion. Methods: This multi-centre cohort study included six departments of Obstetrics and Gynaecology in Sweden. The study included 1457 women who requested an induced abortion, among whom 742 women responded at the three-month follow-up and 641 women at the six-month follow-up. The Screen Questionnaire-Posttraumatic Stress Disorder (SQ-PTSD) was used for research diagnoses of PTSD and PTSS, and anxiety and depressive symptoms were evaluated by the Hospital Anxiety and Depression Scale (HADS). Measurements were made at the first visit and at three and six months after the abortion. The 95% confidence intervals for the prevalence of lifetime or ongoing PTSD and PTSS were calculated using the normal approximation. The chi-square test and the Student's t-test were used to compare data between groups. Results: The prevalence of ongoing PTSD and PTSS before the abortion was 4.3% and 23.5%, respectively, concomitant with high levels of anxiety and depression. At three months the corresponding rates were 2.0% and 4.6%, at six months 1.9% and 6.1%, respectively. Dropouts had higher rates of PTSD and PTSS. Fifty-one women developed PTSD or PTSS during the observation period. They were young, less well educated, needed counselling, and had high levels of anxiety and depressive symptoms. During the observation period 57 women had trauma experiences, among whom 11 developed PTSD or PTSS and reported a traumatic experience in relation to the abortion. Conclusion: Few women developed PTSD or PTSS after the abortion. The majority did so because of trauma experiences unrelated to the induced abortion. Concomitant symptoms of depression and anxiety call for clinical alertness and support.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 305
Typ av publikation
Typ av innehåll
refereegranskat (279)
övrigt vetenskapligt/konstnärligt (26)
Författare/redaktör
Sundström Poromaa, I ... (171)
Sundström Poromaa, I ... (115)
Skalkidou, Alkistis, ... (47)
Bixo, Marie (35)
Wikström, Anna-Karin ... (34)
Bäckström, Torbjörn (30)
visa fler...
Comasco, Erika, 1982 ... (23)
Nyberg, Sigrid (23)
Skalkidou, Alkistis (22)
Hellgren, Charlotte, ... (19)
Ekselius, Lisa (17)
Comasco, Erika (17)
Wikman, Anna (17)
Engman, Jonas (16)
Åkerud, Helena (16)
Hellgren, Charlotte (16)
Åkerud, Helena, 1972 ... (15)
Poromaa, Inger Sunds ... (15)
Gingnell, Malin, 198 ... (13)
Kask, Kristiina (13)
Gingnell, Malin (12)
Wikström, Johan (11)
Stålberg, Karin (11)
Larsson, Anders (10)
Wikström, Johan, 196 ... (10)
Elenis, Evangelia, 1 ... (10)
Lager, Susanne (10)
Bannbers, Elin (10)
Bergquist, Jonas (9)
Hesselman, Susanne, ... (9)
Skoog Svanberg, Agne ... (9)
Stener-Victorin, Eli ... (9)
Kunovac Kallak, Theo ... (9)
Tapanainen, Juha S (9)
Stavreus-Evers, Anne ... (8)
Lindström, Linda, 19 ... (8)
Lanzenberger, Rupert (8)
Kallak, Theodora Kun ... (8)
Iliadis, Stavros I., ... (8)
Epperson, C. Neill (8)
Dubol, Manon (8)
Fredrikson, Mats (7)
Ahlsson, Fredrik, 19 ... (7)
Lundin, Cecilia (7)
Olovsson, Matts (7)
Andersson, Liselott (7)
Bränn, Emma (7)
Sylvén, Sara (7)
Derntl, Birgit (7)
Baumgart, Juliane, 1 ... (7)
visa färre...
Lärosäte
Uppsala universitet (276)
Umeå universitet (64)
Karolinska Institutet (59)
Örebro universitet (12)
Göteborgs universitet (8)
Mittuniversitetet (4)
visa fler...
Röda Korsets Högskola (4)
Stockholms universitet (3)
Sophiahemmet Högskola (3)
Linköpings universitet (2)
Lunds universitet (2)
Högskolan i Skövde (1)
Marie Cederschiöld högskola (1)
visa färre...
Språk
Engelska (305)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (227)
Samhällsvetenskap (9)
Naturvetenskap (5)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy